Nuvalent Inc Total Assets
Nuvalent Inc total assets. Based on the latest financial reports, Nuvalent Inc (NUVL) holds total assets worth $1.33 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Nuvalent Inc market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Nuvalent Inc (2019–2025)
Total assets of Nuvalent Inc from 2019 to 2025. This chart illustrates how Nuvalent Inc's total assets have evolved over time, based on quarterly financial data. See Nuvalent Inc stock price for real-time trading data and today's change.
Nuvalent Inc - Asset Composition Analysis
Nuvalent Inc Total Assets Breakdown (December 2025)
Nuvalent Inc total assets breakdown as of December 2025. Nuvalent Inc's total assets of $1.33 Billion consist of 98.6% current assets and 1.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Nuvalent Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NUVL net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nuvalent Inc's current assets represent 98.6% of total assets in 2025, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 18.5% of total assets in 2025, down from 91.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Nuvalent Inc Competitors by Total Assets
Key competitors of Nuvalent Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Nuvalent Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.14 | 14.48 | 23.89 |
| Quick Ratio | 16.14 | 14.48 | 23.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.23 Billion | $1.01 Billion | $133.45 Million |
Nuvalent Inc - Advanced Valuation Insights
This section examines the relationship between Nuvalent Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.32 |
| Latest Market Cap to Assets Ratio | 6.45 |
| Asset Growth Rate (YoY) | 23.7% |
| Total Assets | $1.41 Billion |
| Market Capitalization | $9.12 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Nuvalent Inc's assets at a significant premium (6.45x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Nuvalent Inc's assets grew by 23.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nuvalent Inc (2019–2025)
The table below shows the annual total assets of Nuvalent Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.41 Billion | +23.73% |
| 2024-12-31 | $1.14 Billion | +55.90% |
| 2023-12-31 | $732.38 Million | +51.80% |
| 2022-12-31 | $482.46 Million | +64.20% |
| 2021-12-31 | $293.82 Million | +2659.95% |
| 2020-12-31 | $10.65 Million | +221.05% |
| 2019-12-31 | $3.32 Million | -- |
About Nuvalent Inc
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine k… Read more